ORPH.L Regulatory News (ORPH)

Open Orphan plc

("Open Orphan or the "Company")

Total Voting Rights

At 9 December 2019 the Company's capital consisted of 254,572,567 ordinary shares of 0.1 pence each in issue with International Securities Identification Number GB00B9275X97. This figure (254,572,567) may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

For further information please contact:

Open Orphan plc +353 (0)1 644 0007

Cathal Friel, Chief Executive Officer

Arden Partners plc (Nominated Adviser and Joint Broker) +44 (0)20 7614 5900

John Llewellyn-Lloyd / Benjamin Cryer

Davy (Euronext Growth Adviser and Joint Broker) +353 (0)1 679 6363

Anthony Farrell

Camarco (Financial PR) +44 (0)20 3757 4980

Tom Huddart / Billy Clegg / Daniel Sherwen

Notes to Editors:

Open Orphan plc is a European-focussed, rare and orphan drug consulting services platform. The Company consists of four elements: a European clinical research organisation and consultancy; an orphan drug services business; a Virtual Rep and Data Access Platform consisting of physicians and key opinion leaders; and a Health Data Platform to partner with Patient Advocacy Groups. The Company is targeting rapid growth in one of the fastest growing sectors in the global pharmaceutical industry targeting under-supplied treatment for life threatening or very serious diseases and rare disorders.